Methylation of the promoter of human leukocyte antigen class I in human esophageal squamous cell carcinoma and its histopathological characteristics

Journal of Thoracic and Cardiovascular Surgery

Volumn 141, Issue 3, 2011, Pages 808-814

  Qifeng, Sun ^a   Bo, Cong ^a   Xingtao, Jiang ^a   Chuanliang, Peng ^a   Xiaogang, Zhao ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

antigen processing machinery; APM; ESCC; esophageal squamous cell carcinoma; HLA I; human leukocyte antigen class I; LMP2; low molecular weight protein 2; PCR; polymerase chain reaction; TAP1; transporter associated with antigen processing 1

Indexed keywords

ANTIGEN; CARRIER PROTEIN; FORMALDEHYDE; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 1 MONOCLONAL ANTIBODY; LOW MOLECULAR WEIGHT PROTEIN; MONOCLONAL ANTIBODY; ONCOPROTEIN; PARAFFIN; TRANSPORTER ASSOCIATED ANTIGEN PROCESSING 1; UNCLASSIFIED DRUG;

ADULT; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CANCER PATIENT; CANCER SURGERY; CONTROLLED STUDY; DISEASE SEVERITY; EMBEDDING; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; FROZEN SECTION; GENE EXPRESSION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN METHYLATION; RECEPTOR DOWN REGULATION; TUMOR VOLUME;

ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA, SQUAMOUS CELL; CHI-SQUARE DISTRIBUTION; CHINA; CPG ISLANDS; CYSTEINE ENDOPEPTIDASES; DNA METHYLATION; DOWN-REGULATION; ESOPHAGEAL NEOPLASMS; FEMALE; GENOTYPE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MIDDLE AGED; NEOPLASM STAGING; PHENOTYPE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 79951735484     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2010.04.031     Document Type: Article

References (30)

1. Goldminc M, Maddern G, Le Prise E, Meunier B, Campion JP, Launois B. Oesophagectomy by a transhiatal approach or thoracotomy: a prospective randomized trial. Br J Surg. 1993;80:367-70. (Pubitemid 23091543)
2. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:702-9.
3. Mizuki N, Ando H, Kimura M, Ohna S, Miyata S, Yamazaki M, et al. Nucleotide sequence analysis of the HLA class I region spanning the 273-kb segment around the HLA-B and-C genes. Genomics. 1997;42:55-66. (Pubitemid 27215126)
4. Zingg JM, Jones PA. Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. Carcinogenesis. 1997;18:869-82. (Pubitemid 28132329)
5. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 1998;72:141-96. (Pubitemid 27435555)
6. Garrido F, Cabrera T, Accolla RS, et al. HLA and cancer: 12th International Histocompatibility Workshop Study. In: Charron D, ed. HLA genetic diversity of HLA. Vol 1. Functional and medical implication. Paris: EDK; 1997:445-52.
7. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93:9821-6. (Pubitemid 26296693)
8. Flutter B, Gao B. MHC class I antigen presentation: recently trimmed and well presented. Cell Mol Immunol. 2004;1:22-30.
9. Ogino T, Shigyo H, Ishii H, Katayama A, Miyokawa N, Harabuchi Y, et al. HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res. 2006;66:9281-9. (Pubitemid 44521150)
10. Rui-Cabello F, Klein E, Garrido F. MHC antigen on human tumors. Immunol Lett. 1991;29:181-9.
11. Browning M, Dunnion D. HLA and cancer: implications for cancer immunotherapy and vaccination. Eur J Immunogenet. 1997;24:293-312. (Pubitemid 127746453)
12. Nie Y, Yang G, Song Y, Zhao X, So C, Liao J, et al. DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas. Carcinogenesis. 2001;22:1615-23. (Pubitemid 32952138)
13. Hosch SB, Izbicki JR, Pichlmeier U, Stoecklein N, Niendorf A, Knoefel WT, et al. Expression and prognostic significance of immunoregulatory molecules in esophageal cancer. Int J Cancer. 1997;74:582-7. (Pubitemid 28037498)
14. Mizukami Y, Kono K, Maruyama T, Watanabe M, Kawaguchi Y, Kamimura K, et al. Downregulation of HLA class I molecules in the tumor is associated with a poor prognosis in patients with esophageal squamous cell carcinoma. Br J Cancer. 2008;99:1462-7.
15. Zingg JM, Jones PA. Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. Carcinogenesis. 1997;18:869-82. (Pubitemid 28132329)
16. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 1998;72:141-96. (Pubitemid 27435555)
17. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature. 1998;393:386-9. (Pubitemid 28269714)
18. Bird AP, Wolffe AP. Methylation-induced repression-belts, braces and chromatin. Cell. 1999;99:451-4.
19. Hendrich B, Bird A. Mammalian methyltransferases and methyl-CpG- binding domains: protein involved in DNA methylation. Curr Top Microbiol Immunol. 2000;294:55-74. (Pubitemid 30133493)
20. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet. 1999;21:163-7. (Pubitemid 29070360)
21. Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, et al. Aberrant CpG- island methylation has non-random and tumor-type-specific patterns. Nat Genet. 2000;24:132-8.
22. Guillaudeux T, Gomez E, Onno M, et al. Expression of HLA class I genes in meiotic and post-meiotic human spermatogenic cell. Biol Reprod. 1996;55:99-110. (Pubitemid 26293146)
23. Griffioen M, Ouwerkerk IJ, Harten V, Schrier PI. HLA-B down-regulation in human melanoma is mediated by sequences located downstream of the transcription-initiation site. Cancer. 1999;80:573-80. (Pubitemid 29047523)
24. Debruyne L. Treatment of malignancy by direct gene transfer of a foreign MHC class I molecule. Cancer Immunol Immunother. 1996;43:180-9.
25. Momparler RL, Eliopoulos N, Ayoub J. Evaluation of an inhibitor of DNA methylation, 5-aza-2′-deoxycytidine, for the treatment of lung cancer and the future role of gene therapy. Adv Exp Med Biol. 2000;465:433-46. (Pubitemid 32193354)
26. Esteller M. Relevance of DNA methylation in the management of cancer. Lancet Oncol. 2003;4:4351-8.
27. Ehrlich M. DNA methylation in cancer:too much, but also too little. Oncogene. 2002;21:5400-13. (Pubitemid 34983477)
28. Esteller M. CpG island hypermethylation and tumor suppressor genes:a booming present, a brighter future. Oncogene. 2002;21:5427-40. (Pubitemid 34983479)
29. van Groeningen CJ, Leyva A, O'Brien AM, Gall HE, Pinedo HM. Phase I and pharmacokinetic study of 5-aza-2 deoxycytidine(NSC 127716)in cancer patients. Cancer Res. 1986;46:4831-6. (Pubitemid 16000370)
30. Aparicio A, Eads CA, Leong LA, Laird PW, Newman EM, Synold TW, et al. Phase I tria1 of continuous infusion 5-aza-2-deoxvcvtidine. Cancer Chemother Pharmacol. 2003;51. 231-23.